Author: Ryan Allway

The post Emblem and Canntab Therapeutics Announce Health Canada Approval for R&D of Cannabinoid-Based Oral Sustained Release Formulation appeared first on CannabisFN.

Transaction to Create Preeminent Global Cannabis Company

EDMONTON and MARKHAM, ON , May 14, 2018 /CNW/ – Aurora Cannabis Inc. (“Aurora”) (ACB.TO) and MedReleaf Corp. (“MedReleaf”) (LEAF.TO) are pleased to announce that they have entered into a definitive arrangement agreement (the “Arrangement Agreement”) whereby Aurora intends to acquire all of the issued and outstanding common shares of MedReleaf in an all-share transaction valued at approximately C$3.2 billion on a fully diluted basis (the “Transaction”).

Proposed Transaction

Under the terms of the Arrangement Agreement, holders of MedReleaf common shares will receive 3.575 common shares of Aurora for each MedReleaf common share held (the “Exchange Ratio”). Upon completion of the Transaction, existing Aurora and MedReleaf shareholders would own approximately 61% and 39% of the pro forma company, respectively, on a fully diluted basis.

The Exchange Ratio implies a price of C$29.44 per MedReleaf common share and a premium of approximately 34%, based on the 20-day volume weighted average prices of Aurora and MedReleaf common shares on the Toronto Stock Exchange as of May 11, 2018 .

Highlights of the Transaction

The proposed Transaction brings together two of Canada’s premier cannabis companies with fully-aligned strategic visions and production philosophies, as well as complementary assets, distribution networks, products, and capabilities. The combined company will meet what Aurora and MedReleaf management teams consider to be the critical success factors in the industry, creating a powerful platform for accelerated growth on a global scale:

• Industry leading scale: the Transaction brings together two leading operators with a total funded capacity of over 570,000 kg per year of high-quality cannabis, through nine facilities in Canada and two in Denmark .
• Low production costs and industry leading yields: Aurora’s automated greenhouses are expected to deliver industry-leading efficiency and low production costs, delivering sustainably robust margins. MedReleaf’s high-yield cultivation is expected to further enhance productivity and reduce costs across the combined entity’s facilities.
• Extensive distribution channels in Canada and internationally: the two companies have established distribution agreements with Alberta’s Alcanna (formerly Liquor Stores), Quebec’s SAQ, Pharmasave and Shoppers Drug Mart in Canada , among others. Additionally, the companies have a rapidly growing international footprint through a network of in-country sales and distribution capabilities and supply and licensing agreements on five continents, including countries such as Germany , Italy , Brazil and Australia . Both companies are actively engaged in initiatives to further expand their international activities.
• Proven execution and agility across the value chain: creating a combined company, fully integrated across the entire value chain. The combined entity will be enabled to move with more agility and speed to capitalize on diversified opportunities in both the domestic and international markets, and create new, higher-margin opportunities across the value chain.
• Enhanced diversification: a more broadly diversified portfolio of award-winning high-quality flower and derivative products will enable the companies to establish strong brands across the various market segments.
• Brand leadership: three established medical brands, Aurora, CanniMed and MedReleaf, coupled with a portfolio of consumer and wellness brands – San Rafael ’71, Woodstock , and AltaVie – all backed by detailed consumer and marketplace insights and advanced analytical frameworks.
• Innovation and R&D excellence: the expanded scientific team will focus on developing a robust pipeline of marketable IP, accessing higher-margin segments and new revenue streams. Aurora’s Medical Centre of Excellence, formed through the combination of the Aurora and CanniMed science and product development teams, together with MedReleaf’s ongoing studies with recognized research institutes, are expected to continue to evolve product innovation and create additional momentum for brand equity development on a global scale.
• Enhanced capital markets profile: the combined entity’s expanded capital markets profile is expected to appeal to a broader shareholder audience, enhance trading liquidity and increase weighting in index tracking portfolios.

“This is a transformational transaction that brings together two pioneering cannabis companies, both committed to high technology, high quality and low cost production, to create a powerful platform for accelerated growth and success on a global scale,” said Terry Booth , CEO of Aurora. “Our complementary assets, strategic synergies, and strong market positioning will provide us with critical mass and an excellent product portfolio in preparation for the adult consumer use market in Canada . Equally, the combination strengthens our capacity to service the rapidly expanding global medical cannabis markets, and amplifies our early-mover advantage. We are very excited about the combination of our respective science and R&D teams, which will position us exceptionally well for the development of high value-added products, addressing as yet unmet needs in the medical markets, and driving continued innovation for the adult consumer use market.”

Neil Closner , CEO of MedReleaf, added, “MedReleaf was founded on the belief that by striving to be the Medical Grade Standard and bringing the highest level of quality and rigor to the cannabis industry, we would produce safe, consistent, and effective products that help improve the quality of life of our patients and, in time, provide an unrivaled experience for the adult use consumer. This, in turn, would drive growth and opportunity for our business. By combining with Aurora, an integrated producer with an exceptionally strong track record for execution, and deep domestic and international distribution capabilities, we will be ideally positioned to set the global standard for our industry at a pace that will be difficult to match.”

Board of Directors’ Recommendations

The Arrangement Agreement has been unanimously approved by the boards of directors of Aurora and MedReleaf, and each board recommends that their respective shareholders vote in favour of the Transaction.

The board of directors of MedReleaf and the special committee of the MedReleaf board of directors have obtained a fairness opinion from each of Canaccord Genuity Corp. and GMP Securities L.P. that, as of the date of the opinions, and subject to the assumptions, limitations, and qualifications on which such opinions are based, the consideration to be received by MedReleaf’s shareholders pursuant to the Arrangement Agreement is fair, from a financial point of view, to the MedReleaf shareholders. The board of directors of Aurora has obtained an opinion from BMO Capital Markets that, as of the date of the opinion, and subject to the assumptions, limitations, and qualifications on which such opinion is based, the Exchange Ratio provided for in the Arrangement Agreement is fair from a financial point of view to Aurora.

Transaction Summary

The Transaction will be effected by way of a plan of arrangement completed under the Business Corporations Act ( Ontario ). The Transaction will require approval by at least 66 2/3% of the votes cast by the shareholders of MedReleaf present at a special meeting of MedReleaf shareholders. The issuance of Aurora common shares in connection with the Transaction will require the approval of a simple majority of the shareholders of Aurora present at a special meeting. Directors and officers of Aurora and MedReleaf have entered into support agreements pursuant to which they have agreed to vote their shares in favour of the Transaction. In addition, holders of approximately 56% of MedReleaf’s issued and outstanding common shares have entered into irrevocable hard lock-ups to vote their shares in favour of the Transaction.

Upon completion of the Transaction, the board of directors of Aurora will be increased to 8 members, with Norma Beauchamp and Ronald Funk , currently independent Directors of MedReleaf, to be appointed to the board of directors of Aurora.

The Arrangement Agreement includes customary provisions including reciprocal non-solicitation provisions, subject to the right of each of MedReleaf and Aurora to accept a superior proposal in certain circumstances, with both Aurora and MedReleaf having a five business day right to match any such superior proposal for the other party. The Arrangement Agreement also provides for reciprocal termination fees of C$80 million if the Transaction is terminated in certain specified circumstances, as well as the payment of a C$15 million expense reimbursement fee if the Transaction is terminated in certain other specified circumstances.

In addition to shareholder approvals, the Transaction is subject to the receipt of certain regulatory court and stock exchange approvals and the satisfaction of other conditions customary in transactions of this nature.

Further information regarding the Transaction will be included in the information circulars that Aurora and MedReleaf will prepare, file, and mail in due course to their respective shareholders in connection with their special meetings to be held to consider the Transaction. The Arrangement Agreement will be filed on the SEDAR profiles of MedReleaf and Aurora on the SEDAR website at www.sedar.com.

None of the securities to be issued pursuant to the Arrangement Agreement have been or will be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws, and any securities issued in the Arrangement are anticipated to be issued in reliance upon the exemption from such registration requirements provided by Section 3(a)(10) of the U.S. Securities Act and applicable exemptions under state securities laws. This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities.

Advisors and Counsel

BMO Capital Markets is acting as the exclusive financial advisor to Aurora. McMillan LLP is acting as legal counsel to Aurora.

Canaccord Genuity is acting as the exclusive financial advisor to the special committee of the board of directors of MedReleaf, who also received an independent fairness opinion from GMP Securities, and an independent financial diligence report from Deloitte LLP. Stikeman Elliott LLP is acting as legal counsel to MedReleaf. Davies Ward Phillips & Vineberg LLP is acting as legal counsel to shareholders of MedReleaf.

Press Conference and Analyst Call

Aurora and MedReleaf will hold a press conference at 10:00 a.m. Eastern time , details of which have been disseminated via media advisory. The presentation and multi-media assets will be available at: https://investor.auroramj.com/#/investor-info#aurora-medreleaf

Conference Call and Webcast Access Information

Aurora and MedReleaf will host a webcast conference call, including a slide presentation, to discuss the transaction on Monday, May 14, 2018 , at 11:30 a.m. Eastern time .

Participants may join the conference call by dialing (888) 231-8191 or (647) 427-7450.

A live webcast of the conference call, including the slide presentation, will be available at https://bit.ly/2wB9U4z. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software downloads that may be required to join the webcast. To view the webcast presentation with slides, please choose either the Real Streaming Audio or Windows Streaming Audio option.

About Aurora

Aurora’s wholly-owned subsidiary, Aurora Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada’s Access to Cannabis for Medical Purposes Regulations (“ACMPR”). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta , known as “Aurora Mountain”, and a second 40,000 square foot high-technology production facility known as “Aurora Vie” in Pointe-Claire, Quebec on Montreal’s West Island. In January 2018 , Aurora’s 800,000 square foot flagship cultivation facility, Aurora Sky, located at the Edmonton International Airport, was licensed. Once at full capacity, Aurora Sky is expected to produce over 100,000 kg per annum of cannabis. Aurora is completing a facility in Lachute, Quebec utilizing its wholly owned subsidiary Aurora Larssen Projects Inc.

The Company’s wholly-owned subsidiary CanniMed Therapeutics Inc. (“CanniMed”) is Canada’s most experienced licensed producer of medical cannabis, with over 20,000 kg per annum in funded capacity. CanniMed forms the heart of Aurora’s Medical Cannabis Centre of Excellence, aimed at product and market development.

Aurora also owns Berlin -based Pedanios GmbH, the leading wholesale importer, exporter, and distributor of medical cannabis in the European Union. The Company owns 51% of Aurora Nordic, which will be constructing a 1,000,000 square foot hybrid greenhouse in Odense, Denmark . The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens.

Aurora holds a 25% ownership interest in Alcanna Inc. (formerly Liquor Stores N.A.), (TSX:CLIQ) who are developing a cannabis retail network in Western Canada . In addition, the Company holds approximately 17.23% of the issued shares in extraction technology company Radient Technologies Inc, and has a strategic investment in Hempco Food and Fiber Inc., with options to increase ownership stake to over 50%. Aurora is also the cornerstone investor in two other licensed producers, with a 22.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis, and a 17.62% stake in Canadian producer The Green Organic Dutchman Ltd., with options to increase to majority ownership.

Aurora’s Common Shares trade on the TSX under the symbol “ACB”, and are a constituent of the S&P/TSX Composite Index

About MedReleaf

Voted Top Licensed Producer at the 2017 Lift Canadian Cannabis Awards, MedReleaf is an R&D-driven company dedicated to innovation, operational excellence and the production of top-quality cannabis. Sourced from around the world and carefully cultivated in one of two state of the art ICH-GMP and ISO 9001 certified facilities in Ontario, the Company delivers a variety of premium products for the global medical market and is committed to serving the therapeutic needs of its medical patients and providing a compelling product assortment for the adult-use recreational consumer. For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleaf.

Forward looking statements

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain information in this news release constitutes forward-looking statements under applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “potential”, “believe”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, statements with respect to accretive earnings, anticipated benefits associated with the acquisition of MedReleaf, statements with respect to the effect of the Transaction on the combined company and its strategy going forward, the completion of any capital project or expansions, the timing for the completion of the Transaction; the consideration to be received by shareholders of MedReleaf, which may fluctuate in value due to Aurora common shares forming the consideration; the satisfaction of closing conditions including, without limitation (i) required Aurora and MedReleaf shareholder approvals; (ii) necessary court approval in connection with the plan of arrangement, (iii) receipt of any required approvals under the Competition Act; (iv) certain termination rights available to the parties under the Arrangement Agreement; (v) Aurora obtaining the necessary approvals from the TSX for the listing of its common shares in connection with the Transaction; and (vi) other closing conditions, including, without limitation, compliance by Aurora and MedReleaf with various covenants contained in the Arrangement Agreement. In particular, there can be no assurance that the Transaction will be completed. Forward looking statements are based on certain assumptions regarding Aurora and MedReleaf, including expected growth, results of operations, performance, industry trends and growth opportunities. While Aurora and MedReleaf consider these assumptions to be reasonable, based on information currently available, they may prove to be incorrect. Readers are cautioned not to place undue reliance on forward-looking statements. Forward-looking statements also necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; future legislative and regulatory developments; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; the cannabis industry in Canada generally, income tax and regulatory matters; the ability of Aurora to implement its business strategies; competition; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.

Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect our expectations as of the date hereof, and thus are subject to change thereafter. Aurora and MedReleaf disclaim any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. Factors that could cause anticipated opportunities and actual results to differ materially include, but are not limited to, matters referred to above and elsewhere in Aurora’s MedReleaf’s public filings and the material change reports that will be filed in respect of this Transaction, which are, or will be, available on SEDAR.

Notice to U.S. Holders. Both Aurora and MedReleaf have been formed outside of the United States . Transaction will be subject to disclosure requirements of Canada that are different from those of the United States . Financial statements included in the documents, if any, will be prepared in accordance with Canadian accounting standards and may not be comparable to the financial statements of United States companies. It may be difficult for a securityholder in the United States to enforce his/her/its rights and any claim a securityholder may have arising under the U.S. federal securities laws, since the companies are located in Canada , and some or all of their officers or directors may be residents of Canada or another country outside of the United States . A securityholder may not be able to sue a Canadian company or its officers or directors in a court in Canada or elsewhere outside of the United States for violations of U.S. securities laws. It may be difficult to compel a Canadian company and its affiliates to subject themselves to a U.S. court’s judgment.

AURORA CANNABIS INC.	MEDRELEAF CORP.
Terry Booth	Neil Closner
CEO	CEO

More

View original content:http://www.prnewswire.com/news-releases/aurora-cannabis-to-acquire-medreleaf-300647512.html

SOURCE Aurora Cannabis Inc.

The post Aurora Cannabis to Acquire MedReleaf appeared first on CannabisFN.

The post The Green Organic Dutchman Appoints Cam Battley to Board of Directors appeared first on CannabisFN.

William Gildea, CEO & Chairman
888-387-3761
bill@futurefarmtech.com

The post Future Farm Sells 10% Ownership Interest in Arizona Medical Marijuana Cultivation and Processing Management Company to Solis Tek appeared first on CannabisFN.

VANCOUVER, BC, May 10, 2018 – Koios Beverage Corp. (CSE: KBEV; OTC: SNOVF) (the “Company” or “Koios”), is pleased to announce the creation of Cannavated Beverage Co. (“Cannavated”), a wholly-owned subsidiary that will be among the first companies to produce cannabis-infused beverages.

Koios brings its proven experience in the functional beverage industry to the growing cannabis sector. Cannavated drinks will have all of the nootropic health benefits of the winning Koios drink formula, and will target medical cannabis users, who have long called for more choice in the market.

“The industry has proven it is going in the direction of cannabis-infused drinks,” said Chris Miller, CEO of Koios. “It’s healthier. Nobody wants to smoke anymore. The market for beverages is vast, especially when you consider the aging population and the demand for medical cannabis among seniors.”

Cannavated’s longer-term plans include partnering with licensed producers, cultivators and other regulated cannabis companies who want to sell their own line of cannabis drinks. By entering into a “white labelling” turn-key agreement, companies will be able to sell Cannavated drinks under their own brand names and labels.

“We have used hemp oil in our previous product line due it’s cognitive benefits and perfect balance of omega’s,” added Miller. “Using our existing knowledge and experience in the beverage space not only allows us to help licensed producers, but to also reach a wider audience of health-conscious consumers.  We are especially excited about the possibility of combining CBDs with our proprietary nootropic blend to create a cannabis-based cognitive beverage.”

The introduction of Cannavated enables Koios to target a whole new demographic, increasing its market reach with a broader and expanding base of consumers. Market demand is expected to grow beyond medical users once the Canadian government legalizes cannabis for recreational use, likely to happen later this year.

The functional beverage market is quickly becoming the go-to drink-of-choice among a new generation of consumers who want low-calorie, nutrient-dense options. Koios will supply its proprietary nootropic recipes to Cannavated, ensuring the cannabis drinks have all of the nutrients and flavour that consumers have come to associate with the brand.

About the Company’s Business

The Company, through its wholly-owned subsidiary Koios, Inc., is an emerging functional beverage company which has an available distribution network of more than 2,000 retail locations across the United States in which to sell its products. Koios has relationships with some of the largest and most reputable distributors in the United States, including Europa Sports, Muscle Foods USA, KeHE, and Wishing-U-Well.  Together these distributors represent more than 80,000 bricks and mortar locations across the United States – from sports nutrition stores to large natural grocery chains including Whole Foods and Sunflower markets.  Through its partnership with Wishing-U-Well, Koios also enjoys a large presence online, including being an Amazon choice product.  

Koios uses a proprietary blend of nootropics and natural organic compounds to enhance human productivity without using harmful chemicals or stimulants.  Koios products can enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity.  Its ingredients are specifically designed to target brain function by increasing blood flow, oxygen levels and neural connections in the brain.  

Koios is one of the only drinks in the world to infuse its products with MCT oil.  MCT oil is derived from coconuts and has been shown to help the body burn fat more effectively, create lasting energy from a natural food source, produce ketones in the brain, allowing for greater brain function and clarity, support healthy hormone production and improve immunity. For more information, please visit our website: https://www.mentaltitan.com/

On behalf of the Board of Directors of the Company.

KOIOS BEVERAGE CORP.

“Chris Miller”
Chris Miller, CEO and Director

For further information, please contact:

Paula Arab

Media and Investor Relations Strategist

paula.arab@koiosbeveragecorp.com

403-889-9128

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements with respect to the statement that the Company’s subsidiary will produce cannabis-infused beverages; the statement that the Company will enter into agreements with licensed producers, cultivators and other regulated cannabis companies to produce cannabis-infused beverages; the statement that the market for cannabis-infused beverages is vast and growing; the statement that the legalization of the recreational use of cannabis in Canada is expected to occur later in 2018; and the statement that Cannavated will allow Koios to target a whole new demographic and increase the Company’s market reach. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including: (i) adverse market conditions; (ii) changes to the growth and size of the functional beverage market and the cannabis-infused beverage market; (iii) consumer acceptance and adoption of functional beverages and cannabis-infused beverages as compared to other beverages; (iv) changes to the proposed timeline of the Canadian federal government to pass legislation legalizing the adult recreational use of cannabis; (v) that the Company will not be able to enter into an agreement with a licensed producer, cultivator or other regulated cannabis company for the production of cannabis-infused beverages; (vi) changes to the regulations that apply to the Company and licensed producers, cultivators or other regulated cannabis companies or (vii) regulatory changes which may impact the functional beverage and cannabis-infused beverage market.  Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s documents filed from time-to-time with the British Columbia Securities Commission on SEDAR at www.sedar.com.

Koios has not conducted any scientific studies on the effects of Koios’ products which have been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking Koios’ products will vary from person to person. No claims or guarantees can be made as to the effects of Koios’ products on an individual’s health and wellbeing.

The post Koios Subsidiary, Cannavated, To Develop Line Of Cannabis Functional Beverages appeared first on CannabisFN.

May 9th 2018, VANCOUVER, BRITISH COLUMBIA – CROP Infrastructure Corp. (CSE: CROP) (OTCMKTS: CIICF) (“CROP” or the “Company”) announces that it has entered into a Membership Purchase Agreement dated May 7th 2018 (the “Agreement”) with HUMBOLDT HOLDINGS LLC (“Humboldt”), a limited liability company incorporated under the laws of State of California, whereby the Company has agreed to advance up to US$2,000,000 to Humboldt for land and equipment purchased and the development of a 30,000 square foot greenhouse project intended for lease and brand licensing by Humboldt to licensed cannabis tenant growers (each, “Tenant”) in return for a 30% interest in Humboldt.

The property currently consists of a 10,000 square foot existing cannabis greenhouse and has an existing building permit for the development of an additional 20,000 square feet of canopy. Humboldt intends to lease the property/infrastructure and license its branding to the Tenants. Humboldt also intends to commence construction of additional proprietary greenhouses consisting of 20,000 square feet of canopy. Once completed, the estimated Tenant production is expected to be approximately 2,000 pounds of flower per month. The closing of the transactions contemplated under the Agreement constitute a “Significant Transaction” in accordance with the policies of the Canadian Securities Exchange. To date, the Company has advanced US$1,278,950 and has earned a 30% interest in Humboldt.

The Hempire Company LLC of California is the holder of a 10,000 sqft medical marijuana cultivation license and a 20,000 sqft RRR license and is currently negotiating a tenancy agreement with Humboldt to lease the property and infrastructure and has already commenced cultivation in good faith.

CROP director N. Alex Horsley states, “This acquisition represents our entry into California, the largest cannabis market in the world. Work is now underway on Humboldt’s facility to expand the greenhouse facility to 30,000 square feet of canopy with our new state-of-the-art greenhouse design. CROP continues to aggressively pursue new opportunities to expand its portfolio of tenant growers and infrastructure assets in strategic licensed jurisdictions.”

Transaction

Pursuant to the terms of the Agreement, the Company has agreed to advance up to US$2,000,000 pursuant to an interest free loan which is repayable through 60% of the net after tax profits of Humboldt.  As further incentive for advancement of the loan, the Company was issued a 30% membership interest in Humboldt which is governed by the terms of an operating agreement.

About Humboldt Holdings LLC

Located in Humboldt County California, the property is 8.46 acres and currently houses a 10,000 sqft greenhouse as well as a barn, garage and residence. On site are 5 x 5000 gallon water tanks, a well and pump house and a 30×60 drying shed. The property is zoned for a 10,000 sqft medical and a 20,000 sqft RRR license.

About CROP Infrastructure Corp.

CROP Infrastructure is engaged in the business of investing, constructing, owning, optimizing and branding light supplemented greenhouse projects for lease to cannabis producers and processors offering best-in-class operations. The Company’s main focus is currently California and Washington.

Company Contact

1. Alex Horsley – Director

E-mail: info@cropcorp.com

Phone: (604) 484-4206

Disclaimer for Forward-Looking Information

Certain statements in this press release are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the purchase, development and leasing of projects, commencement of construction of additional greenhouses, estimated Tenant production of product, the pursuit of new opportunities and the expansion of CROP’s portfolio. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding the Company’s ability to execute on its business plan, raise additional funds as and when required, legal and political risks regarding the cannabis industry, including the changes of municipal, state, provincial and federal laws thereof, the risk that Humboldt may require further capital to execute on its expansion plans and other factors beyond the control of the Company. Such forward-looking statements should therefore be construed in light of such factors, and the Company is not under any obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

The post Crop Announces Acquisition of a 30% Interest in California Cannabis Greenhouse Facility appeared first on CannabisFN.

VANCOUVER, BC, May 8, 2018 – Koios Beverage Corp. (CSE: KBEV; OTC: SNOVF) (the “Company” or “Koios”), is pleased to announce a new line of nootropic products today, including a nutritional instant mix powder and daily-use capsule.  The addition of these new products enables Koios to reach a broader audience and target a whole new demographic of customers.

“The powdered version of our supplement was a chance to really push the envelope from an ingredient stand point,” said Chris Miller, CEO and Director.  “We wanted to pack more nutrients and nootropics into one product than any of our competition, while creating some of the better-flavoured supplements on the market.”

The powder is for advanced nootropic users or someone looking for stronger and more intense cognitive benefits that what is found in the line of ready-to-drink products

The new line of capsules uses the same winning formula as the Company’s low-calorie, nutritionally-dense beverages, giving consumers the option of absorbing the active ingredients in capsule-form while on the go.

“Our powders and newly formulated capsules are the result of years of trial-and-error and trying to pack the most value and science we could into one supplement,” said Miller. “These products are in line with our mission: To give people access to a healthier alternative to energy drinks, caffeine and unnatural ingredients.

The new line of powder flavours include Grape Bliss, BlueBerry Lemonade and Sour Apple.

About the Company’s Business

The Company, through its wholly-owned subsidiary Koios, Inc., is an emerging functional beverage company which has an available distribution network of more than 2,000 retail locations across the United States in which to sell its products. Koios has relationships with some of the largest and most reputable distributors in the United States, including Europa Sports, Muscle Foods USA, KeHE, and Wishing-U-Well.  Together these distributors represent more than 80,000 bricks and mortar locations across the United States – from sports nutrition stores to large natural grocery chains including Whole Foods and Sunflower markets.  Through its partnership with Wishing-U-Well, Koios also enjoys a large presence online, including being an Amazon choice product.  

Koios uses a proprietary blend of nootropics and natural organic compounds to enhance human productivity without using harmful chemicals or stimulants.  Koios products can enhance focus, concentration, mental capacity, memory retention, cognitive function, alertness, brain capacity and create all day mental clarity.  Its ingredients are specifically designed to target brain function by increasing blood flow, oxygen levels and neural connections in the brain.  

Koios is one of the only drinks in the world to infuse its products with MCT oil.  MCT oil is derived from coconuts and has been shown to help the body burn fat more effectively, create lasting energy from a natural food source, produce ketones in the brain, allowing for greater brain function and clarity, support healthy hormone production and improve immunity. For more information, please visit our website: https://www.mentaltitan.com/

On behalf of the Board of Directors of the Company.

KOIOS BEVERAGE CORP.

“Chris Miller”
Chris Miller, CEO and Director

For further information, please contact:

Paula Arab

Media and Investor Relations Strategist

paula.arab@koiosbeveragecorp.com

403-889-9128

Forward-Looking Statements

This news release contains forward-looking statements. All statements, other than statements of historical fact that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future are forward-looking statements. Forward-looking statements in this news release include statements with respect to the growth and size of the functional beverage market. The forward-looking statements reflect management’s current expectations based on information currently available and are subject to a number of risks and uncertainties that may cause outcomes to differ materially from those discussed in the forward-looking statements including: (i) adverse market conditions; (ii) changes to the growth and size of the functional beverage market; (iii) consumer acceptance and adoption of functional beverages as compared to other beverages; or (iv) regulatory changes which may impact the functional beverage market.  Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity or performance. Further, any forward-looking statement speaks only as of the date on which such statement is made and, except as required by applicable law, the Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for management to predict all of such factors and to assess in advance the impact of such factors on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statement. Readers should consult all of the information set forth herein and should also refer to the risk factor disclosure outlined in the Company’s documents filed from time-to-time with the British Columbia Securities Commission on SEDAR at www.sedar.com.

Koios has not conducted any scientific studies on the effects of Koios’ products which have been evaluated by Health Canada or the U.S. Food and Drug Administration. As each individual is different, the benefits, if any, of taking Koios’ products will vary from person to person. No claims or guarantees can be made as to the effects of Koios’ products on an individual’s health and wellbeing.

The post Koios Launches New Instant Mix Powder and Capsule Line appeared first on CannabisFN.

The post The Green Organic Dutchman Assembles World Class Senior Leadership Team appeared first on CannabisFN.

The post Abattis to Commence Construction of Large-Scale Growing Facility on Gabriola Island appeared first on CannabisFN.

The post Choom™ Closes Acquisition of Island Green Cure appeared first on CannabisFN.

The post Future Farm Agrees to Acquire 10% of Arizona Medical Marijuana Cultivation and Processing Management Company appeared first on CannabisFN.

New Emerald operation, one of only six licensed producers in Québec, adds indoor growing capacity of approximately 10,000 kg per annum

The post Emerald Health Therapeutics Acquires Cannabis Licensed Producer in Québec appeared first on CannabisFN.

The post RavenQuest Provides Corporate Update appeared first on CannabisFN.

VANCOUVER, British Columbia, May 2, 2018 /PRNewswire/ —

Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (CSE: FFT.CN) (OTCQX: FFRMF) is pleased to announce that it has entered into a Memorandum of Understanding (the “MOU”) with KOM-Agro Management Services, LLC (“KOM-Agro”) to jointly develop, construct, equip and operate a business enterprise of breeding, cultivating, processing and selling of medical cannabis within the territory of Puerto Rico. Future Farm and KOM-Agro will conduct this new business venture as co-owners of Natural Health Solutions, LLC (“NHS”), a limited liability company organized and existing under the laws of Puerto Rico.

NHS was previously granted a Pre-Qualification of License Approval for the construction, development and operation of an “Establishment for Medical Cannabis for Cultivation” in excess of 20,001 sq./ft. of area.

Complete and definite authorization to effectively operate the pre-qualified Establishment for Medical Cannabis for Cultivation is subject to the Puerto Rico Health Department’s final inspection once construction is complete and NHS is ready to start operations. NHS currently has until July 31, 2018 to apply for the Final Inspection of the Cultivation Facility. It is, however, a condition to Future Farm closing on this transaction that this date has been extended to December 31, 2018.

“We’re very happy to announce our intent to partner with KOM-Agro for the breeding, cultivation and processing of medical marijuana in Puerto Rico,” states William Gildea, Future Farm’s CEO. “It is our belief that Puerto Ricoremains a strong market opportunity and that our efforts in the territory will help strengthen its recovery efforts. Our partnership with KOM-Agro will be a compliment to our business venture with Clinica Verde and allow us to supply, not only our own dispensaries, but other dispensaries located across the island, with quality medical marijuana.”

“We are excited about the opportunity to partner with Future Farm,” says Kermit Ortiz-Morales, the sole member of KOM-Agro and Managing Member of NHS. “Future Farm’s depth of knowledge and experience in marijuana cultivation will allow NHS to hit the ground running once the Department of Health issues our final approvals.”

Medical marijuana is legally used in Puerto Rico to address more than a dozen conditions, including Alzheimer’s, cancer, Lou Gehrig’s disease, Parkinson’s disease, rheumatoid arthritis, Crohn’s disease, epilepsy and more. On October 6, 2017, Puerto Rico’s Department of Cannabis’ board approved allowing patients to go to any open clinic, regardless of the dispensary they had been assigned.

Puerto Rico’s medical marijuana industry has full governmental support, which means the island could become the cannabis tourism mecca of the Caribbean. Importantly, the island’s cannabis law includes a reciprocity policy that allows dispensaries to serve patients visiting Puerto Rico, as long as they hold a medical marijuana card from their home state.

On behalf of the Board,

Future Farm Technologies Inc.

William Gildea, Chairman & CEO

About Future Farm Technologies Inc. 

Future Farm is a Canadian company with holdings throughout North America including California, Massachusetts, Florida, Maine, Puerto Rico and Newfoundland. The Company’s mission is to advance sustainable agriculture through production of wholesale and retail cannabis products, including hemp. As a leader in its field, Future Farm is committed to using only the highest quality processes and products. Towards this goal, the Company acquires or partners with licensed-cannabis operators, and acquires or develops leading technologies in cannabis production, breeding, genetics, and Controlled Environment Agriculture (CEA). Future Farm’s scalable, indoor CEA systems utilize minimal land, water and energy resources. The Company holds an exclusive, worldwide license to use a patented vertical farming technology that, when compared to traditional plant production methods, generates yields up to 10 times greater per square foot of land.

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. The Canadian Securities Exchange has not in any way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. 

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking.  Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements.  Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions.  There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties.  We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.
For further information, contact
William Gildea
Director
+1-888-387-3761

SOURCE Future Farm Technologies Inc.

The post Future Farm Signs MOU to Cultivate Marijuana in Puerto Rico appeared first on CannabisFN.

The post High Hampton Enters into Binding Term Sheet to Acquire Well-Positioned California Cannabis Distribution Team appeared first on CannabisFN.

VANCOUVER, British Columbia, April 30, 2018 (GLOBE NEWSWIRE) —

Ladera Ventures Corp. (TSXV:LV.H) (“Ladera” or the “Company”) is pleased to announce that it has entered into a binding letter agreement dated as of April 27, 2018 (the “Letter Agreement”) with leading Los Angeles-based cannabis company MM Enterprises USA, LLC (“MedMen Enterprises”). The Letter Agreement outlines the proposed terms and conditions pursuant to which Ladera and MedMen Enterprises will effect a business combination that will result in a reverse takeover of Ladera by the securityholders of MedMen Enterprises (the “Proposed Transaction”). The Letter Agreement was negotiated at arm’s length.

MedMen Enterprises has elected to terminate its previously announced binding letter agreement with OutdoorPartner Media Corporation in respect of a proposed business combination in accordance with the terms thereof, and OutdoorPartner Media has consented to such termination.

With vertically integrated operations in three states, including seven licensed stores in California’s newly opened adult-use market, MedMen Enterprises, a limited liability company organized under Delaware law, is one of the most dominant players in the fast-growing cannabis industry. MedMen Enterprises recently completed construction of a 45,000-square-foot factory in Northern Nevada, and MedMen Manhattan, the first-of-a-kind marijuana store in New York, opened on Fifth Avenue on April 20, 2018 on schedule. MedMen Enterprises also recently announced a joint-venture with Cronos Group Inc. to develop products and open MedMen branded stores in Canada’s potential adult-use market.

Terms of the Transaction

The Proposed Transaction will be structured as an amalgamation, arrangement, takeover bid, share purchase or other similar form of transaction or a series of transactions that have a similar effect with Ladera acquiring all voting securities of MedMen Enterprises. The final structure for the Proposed Transaction is subject to satisfactory tax, corporate and securities law advice for both Ladera and MedMen Enterprises.

Completion of the Proposed Transaction is subject to a number of conditions, including completion of the MedMen Financing (defined below), receipt of all necessary shareholder and regulatory approvals, the execution of related transaction documents, approval of the TSX Venture Exchange (the “TSXV”) for the delisting of the common shares of Ladera (the “Ladera Shares”) from the NEX board of the TSXV and conditional approval of the Canadian Securities Exchange for the listing of the Ladera Shares following completion of the Proposed Transaction. Completion of the Proposed Transaction is also subject to conversion of the 8,000,000 subscription receipts (the “Ladera Subscription Receipts”) previously issued by Ladera on March 7, 2018, release to Ladera of the related escrowed funds and cancellation of the warrants of Ladera underlying such subscription receipts.

MedMen Enterprises currently intends to complete a brokered private placement (the “MedMen Financing”) to accredited investors of subscription receipts (the “MedMen Subscription Receipts”). MedMen Enterprises has engaged Cormark Securities Inc. and Canaccord Genuity Corp., leading Canadian independent investment dealers, to act as co-bookrunners in connection with the MedMen Financing. The MedMen Subscription Receipts are proposed to be exchanged for post-Consolidated Ladera Shares in connection with the Proposed Transaction.

In connection with the Proposed Transaction, the Company will be required to, among other things: (i) change its name to a name requested by MedMen Enterprises and acceptable to applicable regulatory authorities; (ii) consolidate its outstanding Ladera Shares on a basis to be determined (the “Consolidation”); (iii) replace all directors and officers of the Company on closing of the Proposed Transaction with nominees of MedMen Enterprises; and (iv) create a new class of non-participating super voting shares that would be issued to the founders of MedMen, Adam Bierman and Andrew Modlin, under the Proposed Transaction.

Under the Proposed Transaction, existing shareholders of the Company as of immediately prior to the completion of the Proposed Transaction would hold post-Consolidated Ladera Shares (whose voting rights will be subordinated) with a value, based on the MedMen Financing price, of US$6.0 million. Further details of the Proposed Transaction will be included in subsequent news releases and disclosure documents (which will include business and financial information in respect of MedMen) to be filed by the Company in connection with the Proposed Transaction. It is anticipated that an annual general and special shareholder meeting of the Company to approve, among other matters, all required matters in connection with the Proposed Transaction will take place in May 2018 and closing of the Proposed Transaction will take place in the second quarter of 2018.

The Common Shares of the Company will remain halted until all necessary filings have been accepted by applicable regulatory authorities.

For more information please contact the Company at 778-331-8505 or email: sackerman@emprisecapital.com

On Behalf of the Board of Directors of Ladera Ventures Corp.
Scott Ackerman
Director

All information contained in this news release with respect to MedMen Enterprises was supplied by MedMen Enterprises for inclusion herein and the Company has relied on the accuracy of such information without independent verification.

As noted above, completion of the Proposed Transaction is subject to a number of conditions, including but not limited to, majority of the minority shareholder approval of the voluntary delisting of the Ladera Shares from the NEX board of the TSXV and TSXV acceptance of such delisting. The Proposed Transaction cannot close until the required shareholder approval is obtained in respect of the applicable matters. There can be no assurance that the Proposed Transaction will be completed as proposed or at all.

Investors are cautioned that, except as disclosed in the management information circular or listing statement of the Company to be prepared in connection with the Proposed Transaction, any information released or received with respect to the Proposed Transaction may not be accurate or complete and should not be relied upon. Trading in the securities of Ladera should be considered highly speculative.

The TSX Venture Exchange Inc. has in no way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this news release.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities under the MedMen Financing in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Forward-Looking Information and Statements

This press release contains certain “forward-looking information” within the meaning of applicable Canadian securities legislation and may also contain statements that may constitute “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current condition, but instead represent only the Company’s beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company’s control. Generally, such forward-looking information or forward-looking statements can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or may contain statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “will continue”, “will occur” or “will be achieved”. The forward-looking information and forward-looking statements contained herein may include, but are not limited to, information concerning the Proposed Transaction and the MedMen Financing, expectations regarding whether the Proposed Transaction will be consummated, including whether conditions to the consummation of the Proposed Transaction will be satisfied, the timing for holding the annual general and special meeting of shareholders of the Company and the timing for completing the Proposed Transaction, expectations for the effects of the Proposed Transaction or the ability of the combined company to successfully achieve business objectives, expectations regarding whether the MedMen Financing will be consummated, and expectations for other economic, business, and/or competitive factors.

By identifying such information and statements in this manner, the Company is alerting the reader that such information and statements are subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied by such information and statements. In addition, in connection with the forward-looking information and forward-looking statements contained in this press release, the Company has made certain assumptions. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information and statements are the following: the ability to consummate the Proposed Transaction and the MedMen Financing; the ability to obtain requisite regulatory and shareholder and unitholder approvals and the satisfaction of other conditions to the consummation of the Proposed Transaction on the proposed terms and schedule; the ability to satisfy the conditions to the consummation of the MedMen Financing or to the conversion of the MedMen Subscription Receipts; the potential impact of the announcement or consummation of the Proposed Transaction on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time on the Proposed Transaction and the MedMen Financing. Should one or more of these risks, uncertainties or other factors materialize, or should assumptions underlying the forward-looking information or statements prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected.

Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws. All subsequent written and oral forward- looking information and statements attributable to the Company or persons acting on its behalf is expressly qualified in its entirety by this notice.

The post Ladera Ventures Announces Proposed Reverse Takeover By MedMen Enterprises appeared first on CannabisFN.

The post Abattis Completes Acquisition of Remaining Minority Interest in Gabriola Green Farms appeared first on CannabisFN.

Nuka’s 1906 chocolates, utilizing Lexaria’s DehydraTECH technology, have been recognized for their fast onset times, efficacy, amazing taste and unique formulations

Kelowna, British Columbia – April 30, 2018 – Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX), an innovator in drug delivery platforms, today announced a major new licensing agreement with Nuka Enterprises LLC, maker of 1906 brand cannabis chocolates and other edible products. The deal renews Nuka’s DehydraTECHTM license rights for use in its 1906 brand of cannabis chocolates, recognized for their fast onset times, efficacy, amazing taste and unique formulations.

Nuka has been utilizing Lexaria’s technology within its award-winning 1906 brand chocolates for nearly two years, during which time 1906 entered the cannabis market; advanced from a start-up to Colorado’s number-three cannabis chocolate brand available in over 150 locations; and touted by media, industry watchers and consumers as one of the most innovative brands in the cannabis space.

“1906 products are a unique combination of nature and science, bringing together natural plant medicines delivered in delicious form factors such as chocolate with advanced technologies that make them safe, predictable, fast-acting and efficacious,” said Peter Barsoom, CEO of Nuka Enterprises, LLC. “We’ve worked closely with Lexaria through 1906’s development and launch phases to create the best possible products that taste great, reduce onset times and deliver amazing experiences. Fast-acting edibles are the wave of the future – it’s what consumers want – and we are at the forefront of bringing innovations to address consumer needs.”

The comprehensive 10-year agreement provides Nuka and 1906 with competitive technological advantages, as well as growing revenue streams for Lexaria. The semi-exclusive deal provides Nuka and 1906 with the immediate ability to utilize DehydraTECHTM technology across the US. Initially, 1906 will focus on recreational and adult-use states such as Colorado, Nevada, California, New Jersey, and Massachusetts. Nuka has also acquired an option to expand its products and brand to Canada, including through the use of Lexaria’s existing chocolate and confections contract manufacturer licensee Cannfections Group Inc.

Nuka and 1906 will leverage the competitive advantages of DehydraTECHTM across multiple product lines, as they have also strategically acquired new rights in product categories in addition to the original chocolate formats, which include candies, beverages, capsules and pills, and topical creams. In doing so, Nuka and 1906 have the opportunity to create America’s first national DehydraTECHTM-powered cannabis brand for edible and topical products that offer the superior experiential profiles 1906 consumers desire, together with the exceptional flavor and speed of onset benefits.  

“Nuka was our first commercial client and has been an ideal partner due to their focus on using technology and advanced science as a competitive advantage,” said Chris Bunka, Chief Executive Officer of Lexaria Bioscience Corp. “Nuka’s success with the 1906 brand of cannabis chocolates – recognized for their fast onset times, efficacy, taste and unique formulations – clearly demonstrate the market potential for DehydraTECHTM. This comprehensive, long-term relationship between Nuka and Lexaria is poised to redefine the cannabis industry and holds great potential for us in other markets.”

About Nuka Enterprises and 1906

Nuka Enterprises develops processes, IP and services, focused on disrupting the nascent and fast emerging cannabis industry. Nuka’s 1906 brand is creating a new category of premium edibles, marrying the benefits of cacao, cannabis and ethnobotanical ingredients, designed to appeal to responsible, informed, health conscious adults. Products that deliver absolutely safe, consistent and predictable experiences, helping customers re-connect with your senses and addressing different experiences with truly exceptional tastes. For more information, please visit www.1906newhighs.com

About Lexaria

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria’s technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter (https://twitter.com/lexariacorp)

and on Facebook http://tinyurl.com/y8vzcaam

FOR FURTHER INFORMATION PLEASE CONTACT:

Lexaria Bioscience Corp.

Alex Blanchard, Communications Manager

(778) 796-1897

Or

NetworkNewsWire (NNW)

www.NetworkNewsWire.com

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. The Company makes forward-looking public statements concerning its expected future financial position,

The post Lexaria Technology Brings “Fast-Acting” to Nuka’s 1906 Cannabis Products with 10-Year Deal Consummating Proof-Of-Concept Relationship appeared first on CannabisFN.

The cannabis industry is expected to reach $50 billion by 2026 in the U.S. and C$22.6 billion over the coming years in Canada, according to industry analysts. While cannabis flower still commands the most sales, cannabis-infused products have become the fastest-growing segment across North America. Investors may want to look at companies serving this unique market segment, particularly as recreational legalization goes into effect.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) recently announced a definitive technology licensing agreement with GP Holdings LLC, a developer of cannabis infused beverages, providing access to its breakthrough technology that enhances bioavailability.

Cannabis Beverage Market

Constellation Brands’ (NYSE: STZ) purchase of a 9.9 percent equity stake in Canopy Growth (TSX: WEED) for $191 million sent shockwaves through the cannabis community in October of 2017. Constellation Brands President and CEO Rob Sands said that the nationwide legalization of marijuana will occur in the United States, but in the meantime, the company would start to sell in countries where recreational marijuana is already legal.

Specialty beverage companies had already been coming out with new cannabinoid infused beverages before the deal, but the move signaled that larger players in the multi-billion dollar beverage industry may be interested in expanding. Given the size of the alcohol industry, many of these companies may see cannabis-infused beverages as a market that could become just as large and offer a different type of effect upon consumption.

In July 2019, the Cannabis Drinks Expo will debut in San Francisco to bring together drinks producers, manufacturers, brand owners, distilleries, and breweries, along with the beverage supply chain to discuss the implications of legal cannabis. Events like these could open up the market to more established beverage companies looking to build a presence in the industry by incorporating cannabinoids into their products in newly legal markets.

California’s cannabis beverage market is expected to become one of the largest edible product segments following the state’s legalization of recreational cannabis this year. Arcview Market Research, in partnership with New Frontier, estimated that California’s market could reach $6.5 billion by 2020, driven by the legalization of recreational cannabis. These figures translate into an enormous market opportunity for companies competing in the space.

DehydraTECH’s Advantage

Lexaria’s patented DehydraTECH™ technology is designed to increase the bioavailability, improve the flavors, and rapidity of onset of cannabinoids across a wide range of products, including beverages.

In late-April, the company announced a deal with GP Holdings LLC to leverage the technology to bring cannabis-infused beverages to market in California. GP Holdings aims to become a leading THC beverage contract manufacturer in the state with a new state-of-the-art bottling facility coming online within the next two quarters. The two companies have been collaborating for months on integrating DehydraTECH™ into its formulations.

“The use of DehydraTECH™ triggers a race to the top in the California THC beverage and topicals market through this 5-year license agreement,” said Lexaria CEO Chris Bunka in the press release announcing the deal. “This is another long-term strategic relationship that will give consumers the faster acting and highly potent products they deserve, and class leading flavor profiles for the beverage segment in particular.”

Under the terms of the agreement, Lexaria provided GP Holdings with semi-exclusive rights for five years in exchange for a lump sum and royalty on revenue generated from products developed using its DehydraTECH™ technology. The agreement enables Lexaria to generate near-term revenue while still offering other licensee partners the option of using GP’s formulation and expertise to produce cannabis-infused beverages in the state.

Looking Ahead

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has made tremendous progress in commercializing its DehydraTECH™ technology. In addition to the GP Holdings agreement, the company announced a deal with Hill Street Beverage Co. to develop cannabis-infused alcohol-free beers and wines in Canada. These types of deals should create steady recurring cash flow and exceptional long-term value for shareholders.

For more information, visit the company’s website or download their investor presentation.

Disclaimer 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

The post Lexaria’s DehydraTECH Builds Market Share in Cannabis Beverage Industry appeared first on CannabisFN.

The post Village Farms International announces Pure Sunfarms’ cannabis supply agreement with Emerald Health Therapeutics appeared first on CannabisFN.